Pipeline, Timeline & Milestones Mission
Drug Candidate
Molecule
Disease
Non clinical | Phase 1-2
Pivotal Trial Completion
Approval
Market size
NS 001
Naloxone
Opioid overdose
Phase 2 completed (n= 14)
Q 1 2021
Q 1 2022
$ 1.0 B
NS 002
Epinephrine
Anaphylactic shock
Phase 2 completed
Q 1 2022
Q 1 2023
$ 1.5 B
NS 003
Midazolam
Seizures
In vitro feasibility TBD 2021
$ 4.0 B
NS 004
Atropine
Chemical warfare
In vitro feasibility TBD 2021
Mostly defense related
$ 1.0 B (Estimate)
NS 005
Metoclopramide
Intractable vomiting
R&D TBD 2021
$ 2.0 B